Showing 6401-6410 of 9855 results for "".
- Skin Cancer Survey Spotlights Frustration with Perceptions of "Less Serious" Conditionhttps://practicaldermatology.com/news/skin-cancer-survey-spotlights-frustration-with-perceptions-of-less-serious-condition/2457743/People living with skin cancer struggle with perceptions that their condition is less serious than other types of cancer despite significant physical and emotional impact, according to Skin Cancer In America 2018, a national survey by Health Union, LLC of people diagnosed with the condition.
- DermTech: Carcinome Clinical Study Enrollment Completehttps://practicaldermatology.com/news/dermtech-carcinome-clinical-study-enrollment-complete/2457745/DermTech, Inc., the global leader in non-invasive molecular dermatology, announced completion of enrollment in the Carcinome™ clinical study. The goal of the Carcinome™ study is to develop a non-invasive genomic test to differentiate basal cell carcinoma (BCC) and squamous cell
- Severe AD Linked to CV Risk in Large Trialhttps://practicaldermatology.com/news/severe-ad-linked-to-cv-risk-in-large-trial/2457748/Eczema now joins the list of inflammatory conditions linked to cardiovascular risk. British researchers report that individuals with severe eczema may be at greater risk for heart attack, stroke and atrial fibrillation. Their study appears in the
- Rapamycin Lotion Reduces Facial Tumors Caused by Tuberous Sclerosishttps://practicaldermatology.com/news/rapamycin-lotion-reduces-facial-tumors-caused-by-tuberous/2457750/Rapamycin lotion significantly reduced the disfiguring facial tumors affecting more than 90 percent of people with tuberous sclerosis complex (TSC), researchers from The University of Texas Health Science Center at Houston (UTHealth) report. Findings of the multicenter, international stud
- Skincare on Trial: Revision Introduces New Patient-Friendly Optionhttps://practicaldermatology.com/news/skincare-on-trial-revision-introduces-new-patient-friendly-option/2457752/Revision Skincare has introduced a collection of five comprehensive 45-day trial regimens they say are designed to address the needs of
- EWG: Two-Thirds of Sunscreen Products Offer Poor Protection or Have Worrisome Ingredientshttps://practicaldermatology.com/news/ewg-two-thirds-of-sunscreen-products-offer-poor-protection-or-have-worrisome-ingredients/2457756/The Environmental Working Group (EWG) released its 12th annual Guide to Sunscreens, rating the safety and efficacy of more than 1,000 sunscreens, moisturizers and lip balms that advertise sun protection, and found
- New Guidelines May Slightly Increase Reliability, Accuracy of Melanoma Diagnoseshttps://practicaldermatology.com/news/new-guidelines-may-slightly-increase-reliability-accuracy-of-melanoma-diagnoses/2457759/New guidelines may slightly increase reliability and accuracy of melanoma diagnoses, a new study in JAMA Network Open shows. The American Joint Committee on Cancer recently updated its guidelines for melanoma, and the study researchers found that when pathologists used the new gu
- Greater Skin Cancer Risk Seen in U.S. Military Personnelhttps://practicaldermatology.com/news/greater-skin-cancer-risk-seen-in-us-military-personnel/2457762/U.S. military personnel are more likely to develop skin cancer than the general population, according to a review of nine published studies in the Journal of the American Academy of Dermatology (JADD). The f
- ASDS: Skin Cancer Treatment Ranks as Most-Performed Procedure of 2017https://practicaldermatology.com/news/asds-skin-cancer-treatment-ranks-as-most-performed-procedure-of-2017/2457761/The American Society for Dermatologic Surgery (ASDS) members performed nearly 12 million medically necessary and cosmetic procedures in 2017 – over 10 percent more than 2016 and doubling since 2012. For the sixth year in a row, the 2017 ASDS Survey on Dermatologic Procedures reveale
- Dupixent Improves Moderate-to-Severe Atopic Dermatitis in Adolescentshttps://practicaldermatology.com/news/dupixent-improves-moderate-to-severe-atopic-dermatitis-in-adolescents/2457764/DUPIXENT (dupilumab) performed well in a Phase 3 Trial of inadequately controlled moderate-to-severe atopic dermatitis in adolescents, Regeneron and Sanofi report. In the trial, treatment with DUPIXENT as monotherapy significantly improved measures of overall disease severity, skin c